NCT06122896 Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
| NCT ID | NCT06122896 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Pancreatic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2023-11-21 |
| Primary Completion | 2040-10-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.
Eligibility Criteria
Inclusion Criteria: Participants must meet any of the following: * Individuals with pathogenic/likely pathogenic germline variants in STK11, and age ≥30 years. * Individuals with pathogenic/likely pathogenic germline variants in CDKN2A, and age ≥40 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier). * Individuals with pathogenic/likely pathogenic germline variants in one of the other pancreatic cancer susceptibility genes (ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, EPCAM, PALB2, TP53), and age ≥50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier) AND • Exocrine pancreatic cancer in ≥1 first- or second-degree relative from the same side of (or presumed to be from the same side of) the family as the identified pathogenic/likely pathogenic germline variant. * Individuals with pathogenic/likely pathogenic variants in PRSS1 AND a clinical phenotype consistent wi
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.